BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Support stronger IP and exclusivity protections and enforcement in foreign markets
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHELLE MATHY | — |
Health Issues HCR
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| STEPHANIE A. DYSON | — |
| JOHN RAYMOND GIBSON | — |
| MICHELLE MATHY | — |
| CHUCK SHIH New | — |
| CAROLINE TUCKER New | — |
Medicare/Medicaid MMM
Discussions regarding Medicaid 340B drug discount program Discussions regarding H.R.7647, to provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group heath plans and individual and small group health insurance coverage Discussions related to S.4295, Public Health Emergency Pass-Through Payment Fairness Act of 2020
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY DEMSKE | — |
| CHRISTINA HOCHUL | — |
| MICHELLE MATHY | — |
Pharmacy PHA
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| STEPHANIE A. DYSON | — |
| MICHELLE MATHY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.